Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies

Yousun Chung 1, M.D., 2*, Seungwon Shin 2, Ph.D. 2*, Hyoeun Shim 3, MD, Ph.D. 3, Ji Yeon Sohn 4, M.D., Dong-eun Lee 5, M.S., Hyewon Lee 6, M.D., Ph.D., Hyeon-Seok Eom 6, M.D., Ph.D. 6, Kwang Gi Kim 7, Ph.D., 7 and Sun-Young Kong 3, M.D., Ph.D. 3

1 Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea; 2 Optical Research Team, Magok R&D Campus, Z-tec Co., Ltd., Seoul, Korea; 3 Department of Laboratory Medicine, Center for Diagnostic Oncology, Hospital and Research Institute, National Cancer Center, Goyang, Korea; 4 Department of Laboratory Medicine, Eone Laboratories, Incheon, Korea; 5 Biostatistics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea; 6 Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea; 7 Department of Medical Engineering, Gachon University, Incheon, Korea

Angiogenesis is important for the proliferation and survival of multiple myeloma (MM) cells. Bone marrow (BM) microvessel density (MVD) is a useful marker of angiogenesis and an increase in MVD can be used as a marker of poor prognosis in MM patients. We developed an automated image analyzer to assess MVD from images of BM biopsies stained with anti-CD34 antibodies using two color models. MVD was calculated by merging images from the red and hue channels after eliminating non-microvessels. The analyzer results were compared with those obtained by two experienced hematopathologists in a blinded manner using the 84 BM samples of MM patients. Manual assessment of the MVD by two hematopathologists yielded mean±SD values of 19.4±11.8 and 20.0±11.8. The analyzer generated a mean±SD of 19.5±11.2. The intraclass correlation coefficient (ICC) and Bland-Altman plot of the MVD results demonstrated very good agreement between the automated image analyzer and both hematopathologists (ICC=0.893 [0.840–0.929] and ICC=0.906 [0.859–0.938]). This automated analyzer can provide time- and labor-saving benefits with more objective results in hematology laboratories.

Key Words: Multiple myeloma, Bone marrow, Microvessel density, Analyzer, Development, Automation

The important role of angiogenesis in tumor development and progression is well known [1]. Additionally, the prognostic significance of increased angiogenesis has been demonstrated in a wide range of solid tumors [2-4] and hematologic malignancies [5-7]. Multiple myeloma (MM) is the first hematological malignancy, in which the prognostic relevance of increased bone marrow (BM) microvessels was demonstrated [8]; since then, many studies have reported the prognostic significance of BM
microvessel density (MVD) in MM patients [9, 10]. To estimate angiogenesis grade, MVD is usually defined as the microvessel count per field in “hot spots” of anti-CD34 stained trephine biopsies, as endothelial cell proliferation is particularly active in highly vascularized regions [11].

However, the evaluation of MVD by manual counting is highly labor-intensive and can thus become a burden on hematology laboratories. Moreover, the subjectivity of manual counting can result in inter-observer variability. To provide a more objective and less labor-intensive evaluation, we developed an automated image analyzer to assess MVD in BM biopsies of MM patients. This study protocol was approved by the Institutional Review Board of the National Cancer Center, Korea (IRB no. NCC2015-0078). To the best of our knowledge, this is the first software developed that can automatically evaluate MVD using anti-CD34 staining of BM biopsies.

Two color models were used to assess MVD using images of BM biopsies stained with anti-CD34 antibodies: an RGB (red, green, and blue) model and an HSV (hue, saturation, value) model. The red and hue channels were merged, and a bilateral filter was applied to classify the microvessels. Next, histogram and GLCM (gray level co-occurrence matrix) texture analyses were performed on the labeled microvessels. The feature values of each label were used to distinguish microvessels from non-microvessels by applying a regression equation that was derived by statistical analysis. The final MVD was determined after removing the signal from the non-microvessels. We provided the program files as a Google Drive link (https://drive.google.com/file/d/19HPPKc0NDfEL2JHqwuYj1YnKKcvEfQ/view?usp=sharing). A self-extractable file, MVD Analyzer.tar, which contains NCC_MVDTool.exe, and all other related files are available. The program works only with the Windows operating system.

To evaluate the automated image analyzer, BM biopsy samples from 84 MM patients (median age: 62 years, range: 38–84 years) were used for MVD quantification. The patients included in the study were initially diagnosed as having MM through a comprehensive diagnostic workup at the National Cancer Center, Goyang, Korea, between March 2009 and March 2014. Informed consent was exempted as no personal identification information was collected or used for this study. Paraffin-embedded BM biopsy samples were decalcified in 10% neutral-buffered formalin (Australian Biostain, Pty. Ltd., Traralgon, Australia), according to standard procedures. Thin-layer sections were prepared and stained with hematoxylin and eosin, and anti-CD34 antibodies. Immunohistochemistry (IHC) staining for CD34 was performed using the ultraView Universal DAB Detection Kit (Ventana Medical Systems Inc., Tucson, AZ, USA) on a Ventana Benchmark XT platform (Ventana Medical Systems, Tucson, USA),

Fig. 1. MVD being calculated by the automated image analyzer using an image (×400) of a hot spot from BM section stained with anti-CD34 antibodies. Microvessels are marked by a pink box and the MVD count is displayed at the right upper corner.

Abbreviations: MVD, microvessel density; BM, bone marrow.
according to the manufacturer’s instructions. The slides were first immersed in citrate buffer and boiled for 30 minutes in a microwave for antigen retrieval. The slides were then dewaxed, pretreated with a mild cell-conditioning buffer (CC1, Ventana Medical Systems Inc.), incubated with a 1:500 dilution of a primary antibody against CD34 (clone QBEnd10; Novocastra, Leica Biosystems, Newcastle upon Tyne, UK) for 32 minutes, counterstained by hematoxylin and eosin, and mounted.

The MVD results obtained using the automated image analyzer were compared with manual counting results. For manual counting, MVD was evaluated by two independent hematopathologists in a blinded manner using a microscope (Zeiss, Jena, Germany), as described previously, with some modifications [12]. First, the slides were scanned at 100× magnification to identify areas showing conspicuously increased MVD (hot spots). Three hot spots were identified per slide and stained vessels, including arterioles and venules, were counted in each hot spot at 400× magnification (0.24 mm² covered per spot). Round CD34-positive cells showing distinct nuclei were considered as hematopoietic precursors and were excluded from the analysis. Stained cells in the trabecular bone and periosteum were also excluded from the analysis. Finally, the numbers of vessels in the three hot spots were averaged. The hot spot image at 400× magnification (0.24 mm² covered per spot) was also assessed using

![Fig. 2. Comparison of MVD between manual counting and the automated image analyzer for 84 BM biopsy samples from multiple myeloma patients. (A) Intraclass correlation coefficient. (B) Bland-Altman plot.](image)

Abbreviations: MVD, microvessel density; BM, bone marrow; CI, confidence interval.
the automated image analyzer, and the results from three hot spots per slide were averaged (Fig. 1).

The agreement between the MVD results determined by the hematopathologists and by the automated image analyzer was evaluated by generating an intraclass correlation coefficient (ICC) and Bland-Altman plots. The difference between the MVD results was evaluated by a paired t-test. Statistical analyses were performed using the R software version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). \( P < 0.05 \) was considered statistically significant.

Manual assessment of the MVDs by the two hematopathologists from the 84 BM biopsy samples resulted in a mean ± SD of 19.4 ± 11.8 and 20.0 ± 11.8. The MVD results obtained by the hematopathologists demonstrated very good agreement (ICC [95% confidence interval (CI)], 0.984 [0.974–0.990]). However, there was a statistically significant difference between the results obtained by hematopathologists according to the paired t-test (\( P < 0.001 \)). The automated image analyzer resulted in a mean ± SD of 19.5 ± 11.2. The MVD results by the analyzer exhibited very good agreement with results by both hematopathologists, with few outliers, based on the Bland-Altman plot (ICC = 0.893 [0.840–0.929] and ICC = 0.906 [0.859–0.938]) (Fig. 2). No statistically significant difference was observed between the results by the analyzer and the hematopathologists based on the paired t-test.

We developed an automated image analyzer and evaluated its utility for assessing the MVD in BM biopsy samples from MM patients. The MVD measurement showed a very good agreement between the automated image analyzer and hematopathologists. As the two hematopathologists had over 10 years of experience in their specialty, their results showed a very high correlation. One of the hematopathologists tended to consistently count more microvessels than the other, highlighting the need for a more objective evaluation of MVD, especially in hematology laboratories, where experienced pathologists are not present.

As many studies have provided persuasive evidence that MVD has a significant impact on the clinical outcome of MM patients, ongoing studies are examining novel drugs targeting angiogenesis as combination regimens [13-16]. The routine measurement of MVD in MM patients at initial diagnosis can provide additional information for patient care. Methodologies for the automated analysis of IHC images have been developed recently owing to advances in image processing software, especially for cancer diagnosis [17-19]. Automated methods can provide rapid and accurate results and eliminate any human-related bias. The automated image analyzer we have developed may provide time- and labor-saving benefits and more objective results in hematology laboratories that evaluate the MVD of MM patients.

ACKNOWLEDGEMENTS

We appreciate medical technologists from the Hematologic Laboratory in Department of Laboratory Medicine, National Cancer Center, for their technical assistance in MVD analyses.

AUTHOR CONTRIBUTIONS

SYK, HSE, and HL designed the study. KGK and SS developed the software. HS and JYS performed the experiments and collected the data. YC and DL analyzed and interpreted the data. YC wrote the manuscript. All authors read and approved the manuscript.

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article are reported.

RESEARCH FUNDING

This work was supported by the National Cancer Center (NCC-CDA2015-02) and the National Research Foundation of Korea (2014R1A2A2A01002553).

ORCID

Yousun Chung https://orcid.org/0000-0002-5197-6340
Seungwon Shin https://orcid.org/0000-0002-4389-592X
Hyoeun Shim https://orcid.org/0000-0002-8985-0882
Ji Yeon Sohn https://orcid.org/0000-0003-3457-9834
Dong-eun Lee https://orcid.org/0000-0001-8525-7494
Hyewon Lee https://orcid.org/0000-0002-9562-4101
Hyeon-Seok Eom https://orcid.org/0000-0002-0484-2067
Kwang Gi Kim https://orcid.org/0000-0001-9714-6038
Sun-Young Kong https://orcid.org/0000-0003-0620-4058

REFERENCES

1. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
2. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-55.
3. Galindo-Gallego M, Fernández-Aceñero MJ, Sanz-Ortega J, Aljama A, López-Elzaurdia C. Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 2000;196:607-12.

4. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol 1994;145:510-4.

5. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-13.

6. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.

7. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000;14:1414-8.

8. Vacca A, Ribatti D, Roncalli L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.

9. Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574-7.

10. Rajkumar SV, Leong T, Roche PC, Forseca R, Dispensieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.

11. Siddiqui N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.

12. Bhatt SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006;81:649-56.

13. Yang JZ, Wu XD, Meng JB, Zhang JQ, Sun LX. Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis. Pathol Res Pract 2018;214:1694-9.

14. Rao L, De Veirman K, Giannico D, Saltarelli I, Desantis V, Frassanito MA, et al. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin protein MP0250: a preclinical study. Oncotarget 2018;9:13366-81.

15. Rozic G, Paukov L, Cohen Z, Shapira I, Duek A, Bejamini O, et al. STK40579 as a combination therapy with bortezomib or dexamethasone, in vitro and in vivo multiple myeloma models. Oncotarget 2018;9:31367-79.

16. Ntellas P, Perivoliotis K, Dadouli K, Koukoulis GK, Ioannou M. Microves-sel density as a surrogate prognostic marker in patients with multiple myeloma: A meta-analysis. Acta Haematol 2017;138:77-84.

17. Shi P, Zhong J, Hong J, Huang R, Wang K, Chen Y. Automated Ki-67 quantification of immunohistochemical staining image of human nasopharyngeal carcinoma xenografts. Sci Rep 2016;6:32127.

18. Irshad H, Oh EY, Schmolze D, Quintana LM, Collins L, Tamimi RM, et al. Crowdsourcing scoring of immunohistochemistry images: evaluating performance of the crowd and an automated computational method. Sci Rep 2017;7:43286.

19. Guirado R, Carceller H, Castillo-Gómez E, Castrén E, Nacher J. Automated analysis of images for molecular quantification in immunohistochemistry. Heliyon 2018;4:e00669.